25 results about "Tumor cell membrane" patented technology

The present application relates to a kind of chitosan derivatives, its preparation method and application, belong to biological medical polymer material technical field.The method includes under the action of first catalyst, N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan is dissolved in first solvent, second solvent containing n-hexanoic anhydride is added to the first solvent containing N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan and is reacted, obtains chitosan derivative.The preparation method of the present application is easy to obtain raw material, and reaction condition is mild;And the chitosan derivative obtained carries a large number of positive charge, can be combined to the surface of negative electric tumor cell membrane by electrostatic interaction, promotes the interaction between the hydrophobic part of chitosan derivative and cell membrane phospholipid hydrophobic chain, destroys cell membrane stability and finally causes membrane lysis to make tumor cell necrosis.

The application discloses a kind of for sensitizing lung cancer radiotherapy biomimetic nano delivery system and preparation method and application, it belongs to the field of biological medicine, wherein, biomimetic nano delivery system is core-shell structure, including core and the shell of the core outer layer being wrapped;Wherein, core is the lipid nanoparticle of therapeutic nucleic acid being loaded;Shell is tumor cell membrane vesicle;Therapeutic nucleic acid is the short hairpin RNA expression plasmid of targeted deubiquitinating enzyme CYLD gene.The application solves lung cancer radiotherapy resistance problem from mechanism, by therapeutic nucleic acid specific knockdown deubiquitinating enzyme CYLD gene, effectively blocks CYLD / NRP1 signal shaft, to reverse the metabolic reprogramming of tumor cell, significantly enhance its radiotherapy sensitivity, realize to the low-toxicity treatment of radiation resistance lung cancer.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

An anti-tumor pharmaceutical composition based on immune checkpoint blocking and a use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride and a T cell enhancer, the T cell enhancer being at least one of vitamin E and thymosin. By means of a series of in vivo and in vitro experiments, it was found for the first time that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on a tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells. T cell enhancer added on this basis can further increase the number and activity of T cells and significantly enhance the killing ability of T cells after relief from immunosuppression, greatly improving the anti-tumor effect of a drug. The components cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin of the pharmaceutical composition can have a synergistic effect to improve the anti-tumor effect.

This invention relates to the field of biomedical technology, specifically disclosing a biomimetic exosome derived from tumor cell membranes, its preparation method, and its applications. The preparation method of the biomimetic exosomes derived from tumor cell membranes provided by this invention includes the following steps: mixing LLC-derived cell membranes with doxorubicin and resveratrol solutions, and preparing biomimetic exosomes derived from tumor cell membranes by extrusion. The preparation method provided by this invention has advantages such as wide availability of raw materials, simple and controllable process, low technical threshold, and suitability for industrial-scale production. The biomimetic exosomes provided by this invention can effectively induce a specific immune response against tumor cells, achieving the purpose of inhibiting the progression of primary tumors and prolonging the survival of tumor-bearing mice. It can also promote the polarization of macrophages from a pro-tumor M2 phenotype to an anti-tumor M1 phenotype, laying a favorable foundation for the efficient implementation of subsequent immunotherapy and possessing broad application prospects.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.

The application relates to the technical field of magnetic particle imaging, and more particularly to an iron oxide nanoparticle and application of the iron oxide nanoparticle in magnetic particle imaging. The nanoparticle is an octahedral superparamagnetic ferroferric oxide nanoparticle, the nanoparticle is synthesized by adding a surfactant and controlling a reaction rate through a high-temperature thermal decomposition method, the surfactant includes oleic acid and oleylamine, the octahedral superparamagnetic ferroferric oxide nanoparticle is coated with an amphiphilic polymer, the amphiphilic polymer includes polymaleic anhydride-1-octadecenoic acid and polystyrene maleic anhydride copolymer, and the outer layer of the amphiphilic polymer includes biological membranes such as macrophage membranes, red blood cell membranes, neutrophil membranes and tumor cell membranes according to biological application requirements. The surface of the octahedral magnetic particle is a crystal face, the crystal face has low spin disorder and low anisotropy, so that the octahedral magnetic particle has the advantages of low coercivity and high initial magnetic susceptibility, and thus becomes a high-sensitivity magnetic particle imaging tracer.

This invention provides a peptide-human serum albumin (HSA) conjugate drug, its preparation method, and its application. The peptide-human serum albumin conjugate drug comprises a target tumor cell membrane protein peptide, human serum albumin, and a cytotoxin. This invention innovatively introduces an HSA and covalently conjugates the target tumor cell membrane protein peptide and cytotoxin to the HSA, resulting in a conjugate drug with good stability and minimal cytotoxin loss. This peptide-human serum albumin conjugate drug overcomes the technical shortcomings of large molecular weight and cumbersome preparation of ADCs and insufficient drug loading of traditional PDCs, achieving multiple technical advantages such as high drug loading, small molecular weight, and easy preparation, demonstrating significant advantages and promising application prospects. The preparation method provided by this invention is simple and easy to implement, requiring no complex antibody expression and purification processes, resulting in lower production costs.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

This invention discloses a nanomedicine for targeted combination therapy of osteosarcoma, having a core-shell structure, comprising: a nanomedicine core and a biomimetic outer shell. The nanomedicine core is loaded with the active ingredient capsaicin and a near-infrared fluorescent dye; the biomimetic outer shell is an osteosarcoma-derived tumor cell membrane coating the surface of the nanomedicine core. This invention also provides a method for preparing the nanomedicine for targeted combination therapy of osteosarcoma and its applications. The nanomedicine for targeted combination therapy of osteosarcoma provided by this invention possesses excellent "homing" and immune escape capabilities, significantly overcoming the bottleneck of targeted delivery of osteosarcoma, exhibiting significantly better tumor-suppressing effects than single therapy, significantly improving the physicochemical properties and stability of the hydrophobic active ingredient, and possessing good biocompatibility and safety, reducing systemic toxicity.

The present application relates to the technical field of biological medicine, and particularly relates to a tumor immunogenic death biomimetic nanovesicle with high membrane breaking efficiency, a preparation method and application thereof.The tumor immunogenic death biomimetic nanovesicle with high membrane breaking efficiency comprises a tumor cell membrane and a photothermal reagent; the photothermal reagent is compound A or compound B.The biomimetic nanovesicle provided by the present application has a killing rate of more than 95% on various tumor cells, can be prepared into ICMs for different tumors by flexibly matching cell membranes of different cancer types, supports individualized treatment and combined immunotherapy, and provides an innovative scheme with high efficiency, wide spectrum and low toxicity for solid tumor treatment through synergistic action of targeted delivery and photothermal-induced cell membrane destruction, and has high clinical application potential.

The application discloses a VirusTAC platform for tumor cell membrane protein PD-L1 or CD24 targeted degradation and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an IgG Fc region; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain PD-L1 antibody or CD24 antibody. The platform can specifically recognize tumor high-expression receptors and induce rapid endocytosis of cells by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4, so as to overcome the defects of the existing TPD technology and realize effective regulation of various target proteins.

The present application relates to a kind of multifunctional layered double hydroxide (LDH) based therapeutic nano vaccine and preparation method and application.The nano vaccine is loaded with immunoadjuvant CpG and chemotherapeutic drug 5-fluorouracil (5-FU) in turn with LDH as carrier, and further coated with apoptotic tumor cell membrane (aCM), to construct a nano vaccine with immune synergistic therapy function.After being injected into mouse body through tail vein, the LDH-based therapeutic nano vaccine realizes multi-mode combined therapy for tumor through the endoplasmic reticulum stress amplification effect mediated by calcium ion overload, through 5-FU to inhibit DNA synthesis and interfere RNA function in tumor cells, and through the synergistic immune activation mechanism mediated by the double adjuvant system composed of aluminum ion and CpG.The strategy not only significantly inhibits the growth of in situ tumor, but also can induce the body to produce immune memory, and plays an effective tumor prevention effect.

This invention relates to the field of pharmaceutical technology, specifically to a biomimetic nanodelivery system (LLip@PC-GHRK) encapsulated in an MMP-9 / pH dual-responsive fusion membrane, its preparation method, and its applications. The outer layer of this nanocomposite system is a biomimetic membrane LLip fused with tumor cell membranes and liposomes, promoting efficient uptake of biomimetic nanomedicines by tumor cells. The middle layer is coated with pH-responsive units, enabling charge-flipping molecules PLL-CA (PC) to prevent drug degradation in lysosomes. The core is a multifunctional self-assembled polypeptide carrier integrating pH-responsive peptides, cell-penetrating peptides, and nuclear-localizing peptides, capable of loading gene-based drugs. This biomimetic nanodelivery system exhibits good biocompatibility and significantly improves targeted drug delivery efficiency and efficacy through tumor homology targeting, tumor microenvironment responsive activation, and programmed drug release, providing a novel intelligent delivery paradigm for combination cancer therapy.

The application discloses a VirusTAC platform for targeted degradation of tumor cell membrane protein EGFR and psoriasis extracellular pathogenic factor IL17A and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an immunoglobulin Fc region, the Fc regions corresponding to the first polypeptide chain and the second polypeptide chain are associated by heterodimerization mutation; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain EGFR antibody or IL17A antibody. The platform realizes precise degradation of tumor-related membrane proteins and extracellular proteins by constructing a chimera of a natural ligand and a targeting antibody, and by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4.

The application discloses a vanadium carbide nano material capable of enhancing photothermal therapy and application thereof, and relates to the technical field of biomedical materials. The vanadium carbide nano material comprises vanadium carbide nanosheets and cell membrane vesicles. The vanadium carbide nano material is coated with V2C nanosheets through engineering of tumor cell membrane vesicles, target delivery is realized, and the photothermal therapy effect is significantly enhanced by utilizing the characteristic of vanadium elements to block the HSF1 phase separation process. The vanadium carbide nano material integrates multiple functions such as target delivery, photothermal conversion, oxidative stress induction and HSF1 phase separation inhibition, and effectively overcomes the heat tolerance of tumor cells.

This invention relates to the fields of nanomaterials and molecular imaging technology, specifically to a nanomaterial based on self-assembled peptides and bioorthogonal click chemistry, its preparation method, and its applications. The nanomaterial comprises a first peptide nanomaterial and a second peptide nanomaterial. The first peptide nanomaterial contains a GPC3 ligand peptide, a fibrous deformable peptide, and a hydrophobic fluorescent group; the second peptide nanomaterial contains cysteine, a hydrophilic linker motif, a fibrous deformable peptide, and bioorthogonal click chemistry reactive groups. When the two peptide materials are mixed in a specific ratio, they can form spherical nanomaterials in an aqueous solution through hydrophilic-hydrophobic interactions. During in vivo circulation, these nanomaterials, relying on the GPC3 ligand-receptor interaction of the first peptide material, target and accumulate on the surface of HCC cell membranes, further triggering in-situ fibrotic self-assembly, constructing a stable nanofiber network on the tumor cell membrane, thereby anchoring the click chemistry reactive groups to the tumor surface at a high density.

The application belongs to the technical field of medicine, and particularly relates to a cell membrane coated prodrug self-assembled nanoparticle and a preparation method and application thereof. The nanoparticle is a prodrug self-assembled nanoparticle for which a four-sulfur bond bridged cabazitaxel dimer prodrug (gamma-4S-2CTX) and a polyethylene glycol (PEG) modifier are co-assembled to prepare a tumor cell membrane coated with the prodrug self-assembled nanoparticle as a core. The gamma-4S-2CTX is shown in structural formula (I). The biomimetic cell membrane coated nanoparticle (CM-pDPNAs) prepared by the application exhibits significant tumor specific recognition ability and low toxic side effects, greatly improves the selectivity and treatment effect of the drug in the body, and shows good safety and anti-tumor effect in the in-vivo anti-tumor experiment. The application provides an efficient and low-toxic anti-tumor drug delivery system, and has good application prospect.

This invention discloses a cancer vaccine targeting tumor-associated macrophages, its preparation method, and its applications, belonging to the field of biomedical technology. The cancer vaccine comprises hybrid membrane vesicles, a targeting module, and a protease inhibitor. The targeting module is connected to the surface of the hybrid membrane vesicles, and the protease inhibitor is loaded into the lumen of the hybrid membrane vesicles. The hybrid membrane vesicles are obtained by fusing bacterial outer membrane vesicles and tumor cell membrane vesicles, and the targeting module is bonded to the tumor cell membrane vesicles. This cancer vaccine, by efficiently targeting tumor-associated macrophages and dually regulating their phenotype and function, holds the potential to transform them from a pro-tumor population into an anti-tumor population, providing broader application prospects for cancer treatment.

The application discloses a method for recovering membrane antigen of gold corpuscle and constructing nanovaccine based on gravity anchoring. The method comprises the following steps: modifying a first click chemistry reaction group on the surface of tumor cell membrane, providing gold corpuscle modified with a second click chemistry reaction group capable of specifically combining with the first click chemistry reaction group, mixing the modified tumor cell with the gold corpuscle, incubating to anchor the gold corpuscle on the surface of the tumor cell membrane, lysing the tumor cell, and collecting the gold corpuscle-anchored tumor cell membrane antigen complex. The first click chemistry reaction group and the second click chemistry reaction group are a complementary group pair for bio-orthogonal click chemistry reaction. The method realizes the integration of efficient and high-fidelity recovery of membrane antigen and vaccine construction, is simple in process, and is strong in universality. The prepared nanovaccine shows excellent immunotherapy effect in various postoperative recurrence models of tumors.

The application provides an enzymatic polypeptide self-assembly for targeting HER2 protein degradation and an application thereof, and relates to the technical field of biological medicines.The enzymatic polypeptide self-assembly for targeting HER2 protein degradation has the functions of enzyme catalytic cascade activation and enhancement of imaging and targeting HER2 protein degradation.The enzymatic polypeptide self-assembly material organically integrates the imaging unit and the treatment unit into the same carrier, avoids bringing additional physical burden to organisms, and has a good synergistic effect on intuitively and accurately revealing the targeting efficiency of polypeptide compounds targeting tumor cell membrane proteins and improving the accuracy of tumor targeted treatment, solves the problems of low membrane protein degradation efficiency and insufficient targeting in the prior art, provides a new strategy for precise tumor treatment, and has important clinical conversion value and application prospect.

This invention discloses a biomimetic hybrid liposome nanomedicine co-loaded with senolytic drugs and antibiotics, its preparation method, and its applications. The nanomedicine uses egg yolk lecithin and cholesterol as lipid materials. The Bcl-2 / Bcl-xL inhibitor ABT-263 is loaded into a lipid bilayer, and the antibiotic ciprofloxacin hydrochloride is encapsulated in an aqueous core. After preparing co-loaded liposomes using a thin-film hydration-ultrasound-extrusion-ultrafiltration method, the liposomes are fused with doxorubicin-induced senescent tumor cell membranes via ultrasound-assisted physical extrusion. The resulting biomimetic hybrid liposome possesses multiple functions, including homologous targeting of senescent tumor cells, selective removal of senescent cells, and killing of senescent bacteria. Combined use with 5-fluorouracil can enhance the killing effect on senescent tumor cells. This invention belongs to the field of biomedical nanotechnology.

This invention discloses an anti-P2RX4 monoclonal antibody, its preparation method, and its uses. The amino acid sequence of the anti-P2RX4 monoclonal antibody includes a heavy chain as shown in SEQ ID NO.4 and a light chain as shown in SEQ ID NO.6. The advantages of this invention include: developing a specific anti-P2RX4 monoclonal antibody using hybridoma technology targeting the P2RX4 protein; this antibody can recognize the P2RX4 protein on the surface of tumor cell membranes and exhibits certain anti-tumor activity in in vitro and in vivo experiments, showing potential application value for further development into a targeted therapeutic antibody. This invention provides a new tool for basic research in cancer treatment.